Abstract. Two new members
tide exchange factor [GEF] ~) and Sec23p (a Sarlp-specific GTPase activating protein [GAP] ) (Yoshihisa et al., 1993) . Recently, these components in addition to three other soluble proteins have been purified to homogeneity and demonstrated to be sufficient for vesicle budding from the ER in yeast (Nakano et al., 1988; Hicke and Schekman, 1989; d'Enfert et al., 1991; Hicke et al., 1992; Pryer et al., 1993; Salama et al., 1993; Yoshihisa et al., 1993) . In mammalian cells, Sarl function has been indirectly linked to the requirement for/~-COP in vesicle budding from the ER (Peter et al., 1993) . The possible involvement of Sarlp in other steps of the secretory pathway has not been investigated.
To begin to understand the similarities and differences between export from the ER and vesicular traffic through the Golgi apparatus in mammalian cells, we have identified two closely related mammalian homologues of yeast Sarlp (designated Sarla and Sarlb). We find that Sarl, unlike either Art Serafini et al., 1991; Kahn et al., 1992; Taylor et al., 1992; Palmer et al., 1993) or Rabl (Davidson and Balch, 1993; Nuoffer et al., 1994; Pind et al., 1994) , is not required for vesicular traffic between Golgi compartments. These results provide novel evidence that small GTPases (and their associated effectors) regulating vesicle budding from the ER and from compartments of the Golgi may, in part, be distinct. This could reflect differences in the need for these two organdies to recruit cargo to vesicular carriers Pind et al., 1994) .
Materials and Methods

cDNA Cloning
Degenerate oligonucleotide mixtures corresponding to regions of identity among the reported SAR1 protein sequences of Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Arabidopsis thaliana were used to amplify Sarl eDNA from a CHO eDNA library (Uni-ZAP XR; Stratagene, La Jolla, CA) by two stage PCR. The primers used for the first round of amplification were GG(ATG-C)(TC)TIGA(TC)AA(TC)GC(AGTC)GG (codons Gly32-Gly 37, sense) and (GC)(AT)(AG)CACAT(AG)AA(AGTC)-AC(TC)TC (codons Glu174-Ser 179, antisense). The same antisense primer and GA(TC)AA(TC)GC(AGTC)GG(AGTC)AA(AG)AC (codons Asp 34-Thr 4°, sense) were used for the second round of amplification. All nucleotides in parentheses were included at that position. The amplification reactions were performed for five cycles with a denaturing temperature of 940C for 1 rain, annealing at 470C for 1 rain, and elongation at 720C for 2 min, followed by an additional 25 cycles with a denaturing temperature of 94°C for 1 rain, annealing at 55°C for 1 rain, and elongation at 720C for 2 min. For the second round of amplification, the first round reaction was diluted 1O,000-fold and used as the template. The O.4-kb product of the second round amplification was subcloned into a plasmid, pBluescript II (Strata° gene), sequenced, and used as a probe for screening a CHO eDNA library constructed with the bacteriophage k vector (Uni-ZAP XR; Stratagene). Hybridizations were done for 24 h at 65 oC in 5 x SSPE (1 x SSPE --0.15 M NaC1, 1 mM EDTA, 10 mM NaI-i2PO4, pH 7.4), 5x Denhardt's solution, 0.5% SDS, and 100/~g/ml herring sperm DNA. A final wash was performed in lx SSPE, 0.1% SDS at 65°C for 1 h. Eleven positive h clones were isolated, and the DNA inserts with the vector sequence carried by the k clones were rescued by in vivo excision according to the manufacturer's procedure, analyzed by restriction enzyme digestion and partial sequencing, and then restricted to two sets of overlapping cDNAs. Both strands of each of the longest cDNAs termed Sarla and Sarlb DNA, respectively, were fully sequenced with Sequence (United States Biochemical Corp., Cleveland, OH) using walking primers. Plasmids, pBluescript H carrying Sarla and Sarlb cDNA, were termed pBluescript-Sarla and pBluescript-Sarlb, respectively.
Expression of His-tagged Sarla, Sarlb, and Sarla-(T39N) Proteins in Escherichia coli
The coding region of Sarla, Sarlb, and Sarla(T39N) (see below) cDNAs were engineered by PCR to add a BamHI site and a sequence (ATCGAGGG-TAGA) corresponding to a factor Xa cleavage site immediately upstream of the first ATG and to add a HindHI site immediately downstream of the termination codon. The PCR products were digested with BamHI and HindRI and cloned into the pQE9 vector (QIAGEN Inc., Cbatsworth, CA). The resulting plasmids, termed pQE-Sarla, pQE-Sarlb, and pQE-SARIa-T39N, respectively, were introduced into Escherichia coli (MI5 harboring plasmid pREP4; QIAGEN). The transforraants were grown to a density of A600 ffi 0.9 in Super medium (25 g bacto-tryptone, 15 g yeast extract, and 5 g NaC1 per liter with 100/zg/ml arnpicillin and 500/~g/ml kanamycin) at 370C and further cultivated for 2 h in the presence of 2 mM isopropyl-thio-/~-Dgalactoside at 37°C to induce the recombinant proteins.
Purification of His,-tagged Sarl Proteins
Method 1. Hiss-tagged Sarla protein purified by this procedure was used as an antigen to produce polyclonai antibody. E. coli transformants expressing Hiss-tagged Sarla protein were suspended in sonication buffer (50 mM Na-phosphate [pH 8.0], 0.3 M NaCI) containing 1 mg/ml lysozyme, incubated on ice for 10 min, and then disrupted by sonication. The lysate was clarified by centrifugation at 10,000 g for 30 rain, and the supernatant was loaded on a nickel-nitrotriacefic acid (Ni-NTA)-agarose (QIAGEN Inc.) column (8-ml bed volume) previously equilibrated with sonication buffer.
The resin was washed with sonication buffer containing 20 mM imidazole and then Hiss-tagged Sarla protein was eluted with a 100-ml imidazole gradient (20-500 mM) in sonication buffer. Hiss-tagged Sarla protein was pooled and precipitated with 60% saturated ammonium sulfate, dissolved in PBS, and then dialyzed against PBS.
Method 2. Hiss-tagged Sarla proteins purified by this procedure were used for cell-free transport assays. E. coli transformants expressing Hisstagged wild-type Sarla and the T39N mutant were suspended in buffer A (10% glycerol, 150 mM KCI, 5 mM magnesium acetate, 0.1 mM DTT, 20 mM Hepes-KOH, pH 7.0) containing 1 mM PMSF, disrupted in a French press, and then the lysate was clarified by centrifugation at 10,000 g for 30 rain. The supernatant was loaded on a Ni-NTA-agarose column (1-ml bed volume) previously equilibrated with buffer A and washed with buffer A containing 20 mM imidazole. The Hiss-tagged protein was eluted with 7 mi of buffer A containing 100 mM imidazole, precipitated with 60% saturated ammonium sulfate, dissolved in buffer A, and dialyzed against buffer A.
Preparation of Antibody to Sarla Protein
A rabbit was injected with 1 mg purified Hiss-tagged Sarla protein emulsifted in Freund's complete adjuvant, followed with 1 rag purified Hisstagged Sarla protein emulsified in Freund's incomplete adjuvant every three weeks to boost the immune response. Antibody to Sarla protein was aitinitypurified as described (Harlow and Lane, 1988 ) by adsorption to Hisstagged Sarla protein conjugated to AminoLink ° coupling gel (Pierce Chem. Co., Rockford, IL) according to the manufacturer's procedure, precipitated with 60% saturated ammonium sulfate, dissolved in 10 mM MOPS-KOH (pH 7.5) and 150 mM KC1, and dialyzed against the same buffer.
Construction of Sarla Mutants
The T39N and N134I mutations were introduced into the wild-type Sarla sequence carried by pBluescript-Sarla, using site-directed mutngenesis as described (Higuchi et ai., 1988) . The resulting plasmids were termed pBluescript-Sarla-T39N and pBluescript-Sarla-N134I, respectively. For transieni expression of wild-type and mutant Sarla proteins in HeLa cells, the coding regions of wild-type and mutant Sarla cDNAs were engineered by PCR to add a NdeI site immediately upstream of the first ATG and a BamI-II site immediately downstream of the termination codon, using pBluescriptSarla, pBluescript-Sarla-T39N, and pBluescript-Sarla-N134I as templates. The PCR products were digested with NdeI and BamHI, and subcloned into these restriction enzyme sites of the pET3a vector (Novagen, Inc., Madison, WI) for expression from the T7 promoter. All mutant and wild-type Sarl sequences engineered by PCR were verified by DNA sequencing.
Immunoblot Analysis
Proteins were fractionated by 12.5% polyacrylamide SDS-PAGE under reducing conditions (Laemmii, 1970) and electroblotted on to nitrocellulose in 25 mM Tris, 192 mM glycine, and 20% methanol at 22 V/cm for 1 h. Sarl proteins were detected using the affinity-purified anti-Sarla antibody (25 ng/ml) and peroxidase-conjugated anti-rabbit IgG (diluted 1:1,000). Peroxidase labeling was detected by chemiluminescence using the ECL reagent (Amersham Corp., Arlington Heights, IL) according to the manufacturer's recommendations.
Cis-to Mediai-Goigi Transport Assay
The preparation of assay components and standard incubation conditions were as described previously (Balch et al., 1984; Malhotra et al., 1988) . Reactions (50 ~d) contained 25 mM Hepes (pH 7.0), 25 mM KCI, 2.5 mM magnesium acetate, 5 mM creatine phosphate, 0.25 mM UTP, 0.05 mM ATP, 8 IU/ml creatine kinase, 8/~M palmitoyl CoA, 0.4/tM UDP-3H-Nacetylglucosamine ([3H]GlcNac), bovine brain cytosol (5 t~l), donor stacks (5/~1), and acceptor stacks (5/~1). To test the effect of anti-Sarla antibody, the reactions were incubated on ice for 1 h to promote antibody-antigen binding and then incubated at 37°C for assay.
Transport in Semi-intact and PermeabUized Cells
NRK cells were infected with the ts045 strain of vesicular stomatitus virus (VSV) and pulse labeled with 10/tCi Trans [3sS]-label at the restrictive temperature (39.5°C) to accumulate the VSV-glycoprotein (VSV-G) mutant in the ER. The cells were then perforated by the swelling and scraping pro-cedure as described (Balch et al., 1986; Beckers et al., 1987; Davidson and Balch, 1993) . Transport between the ER and the cis/medial-Golgi compartments was measured biochemically by following the appearance of endoglycosidase H (endo H)-resistant forms of VSV-G upon incubation at the permissive temperature (32°C) in the presence of cytosol and ATP as described previously (Plutner et al., 1992; Davidson and Balch, 1993) . Briefly, transport reactions were performed in a final volume of 40/~1 in a buffer containing 25 mM Hepes-KOH (pH 7.2), 75 mM KOAc, 2.5 mM MgOAc, 5 mM EGTA, 1.8 mM CaC12, 1 mM N-acetyl glucosamine, an ATP regenerating system (1 mM ATP, 5 mM creafine phosphate, and 0.2 IU rabbit muscle creatine pbosphokinase, final concentrations), 2-6 /al rat liver cytosol (20-60 ~g/ml protein in 35 rnM Hepes-KOH [pH 7.2], 125 mM KOAc), and 5 ~,1 semi-intact cells (25-30/zg protein or 1-2 x 10 s cells in 50 mM Hepes-KOH [pH 7.2], 90 mM KOAc). The reactions were incubated at 32°C for 2 h, membranes collected by centrifugation, solubilized, digested with endo H, and processed for SDS-PAGE and fluorography as described (Balch et al., 1986; Plumer et al., 1992; Davidson and Balch, 1993) . Autoradiographs were quantitated by a PhosphorImager (Molecular Dynamics, Palo Alto, CA).
For morphological analysis of transport, the cells were permeabilized with digitonin as described (Plntner et al., 1992) . Incubation conditions were as outlined above, except that the reactions were performed in a final volume of 200 ~l. The cells were processed for indirect immunofluorescence as described previously (Balch, 1990; Plutner et al., 1992 ). An antibody specific for ManH (Velaseo et al., 1993) was generously provided by M.G. Farquhar (Division of Cellular and Molecular Medicine, University of California, San Diego, CA).
Transient Expression and Analysis of Transport in HeLa Cells
Experimental procedures for the transient expression of pET-Sarl constructs in HeLa cells were essentially as described previously (Tisdale et al., 1992) . Briefly, cells infected with the T7 RNA polymerasc-recombinant vaccinia virus vTF7-3 (Fuerst et al., 1986) were eotransfected with 1 Izg pAR-G (encoding VSV-G), and 2.5 ~g of the appropriate pET-Sarl constructs using the Transfect ACE TM (GIBCO BRL, Gaithersburg, MD) procedure. After pulse labeling the cells for 10 rain with 20/~Ci Trans [3~S]-label (1,192 Ci/mmol; ICN Biomedicals Inc., Irvine, CA) followed by a 60-rain chase, transport between the ER and the cislmedial-Golgi compartments was assessed biochemically by monitoring the processing of VSV-G for endo H-sensitive to endo H-resistant forms as described (Tisdale et al., 1992; Davidson and Balch, 1993) . For morphological analysis of transport, cells cotransfected with pAR-tsO45-G (encoding the temperature-sensitive tsO45 mutant of VSV-G [Lafay, 1974] ) and appropriate pET-Sarl constructs were incubated at the restrictive temperature (39.5°C) for 4 h to accumulate the protein in the ER. Transport was initiated by shifting the cells to the permissive temperature (32°C). After a 2-h incubation the cells were processed for indirect immunofluorescence as described (Tisdale et al., 1992) .
Immunocytochemistry
Indirect Immunofluorescence. Monolayer cultures of NRK cells, CHOcells, and islet cells of neonatal rat pancreas were fixed with Bouin's fluid. Cells were permeabilized by dehydration and rehydration with ethanol and processed by the immunofluorescence technique. Affinity-purified rabbit antibodies raised against bacterially expressed His6-tagged Sarla protein (40-80 ~g IgG/ml) were applied for 2 h at room temperature in a moist chamber followed by washing with PBS and exposure to FITC-conjugated goat anti-rabbit IgG. Cells were washed with PBS and counterstained with 0.03 % Evans blue before examination with a confocal fluorescence microscope. As a control, preimmune IgG was applied instead of the primary antibody.
lmmunoelectronmicroscopy. Fragments of pancreatic tissue freshly removed from normal adult rats were fixed with 1% gintaraldefiyde in 0.1 M sodium phosphate (pH 7.4). After 1 h of fixation, the tissue was washed with buffer, infiltrated with sucrose, and processed for cryoultramicrotomy as described by Tokuyasu (1980) . Islets of Langerhans isolated from rat pancw, as by collagenase digestion were similarly fixed and processed. Immunolocalization of Sarl on cryosections was carried out by the protein A-gold technique. Thin sections were incubated at room temperature with affinity-porified anti-Sarl antibodies. Sections were subsequently washed with PBS, exposed to the protein A-gold solution (gold particles size 10 rim), and absorption stained with uranyl acetate according to Tokuyasu (1986) .
Quantitative Evaluation. For qnantitation of the immunolabeling, fields of insulin cells showing Golgi regions and associated transitional areas were photographed and printed at a calibrated magnification of 78,864 ×. Transitional areas were defined as the areas of the cytoplasm bordered by transitional elements of the ER and cistemae of the Golgi apparatus, and containing the transfer vesicles. For the quantitative evaluation of Sarl immunolabeling, the transitional areas or the vesicles were delimited with an electronic pen and the number of gold particles in this area was recorded with the same pen connected to a microprocessor programmed to calculate the number of gold particles per unit area (~,m2). Gold particles were also quantitated on RER and Golgi stacks. On the latter, a line was traced in the middle of the stack: the half proximal to the transitional area was quantitated as the cisGolgi, the half distal to the transitional area as trans-Golgi.
CHO (sarla)
MSFIFDWIYS GF$SVLQFLG LYKKTGKLVF LGLDNAGKTT CHO (sarlb) *********E **N******* ****S***** *****~**** S. cerevisiae
SEELTIAGMT FTTFDLGGHI CHO (sarlb) ********** ******** sequences of the members of the SARI family (single letter amino acid code). The ORFs of the corresponding eDNA clones were translated and compared by BESTFIT alignment (Devereux et al., 1984) . The underlined areas indicate conserved GTPbinding domains found in all members of the ras-superfamily Wittinghofer and Pal, 199D . Asterisks denote identity between the CHO Sarla and Sarlb sequences. Consensus (identical) amino acids found in all of the members of the SARI family are shown in the bottom line.
Results
Isolation of Mammalian Homologues of Yeast SARI
Degenerate oligonucleotide mixtures corresponding to regions of homology between the reported S. cerevisiae, S. pombe, and A. thaliana sequences (d 'Enfert et al., 1992) were used to generate DNA fragments from a eDNA library of CHO cells by the polymerase chain reaction. A eDNA fragment that encoded a SARl-like protein was used as a probe to screen a CHO eDNA library. Two different eDNA clones were obtained, both of which encode SARl-like proteins, designated Sarla and Sarlb (Fig. 1) . The mammalian Sarla and Sarlb cDNAs contain open reading frames of 597 nucleotides, encoding proteins of 198 amino acids with predicted molecular masses of 22,413 and 22,388 D, respectively. Fig. 1 shows a comparison of the amino acid sequence of five Sarl proteins cloned to date. Sarla and Sarlb are 91% identical (Table I) . They share 60-67 % identity with yeast and plant Sarlp (Table I ), indicating that the Sarl family is evolutionarily conserved. In contrast, the Sarl proteins are <30% identical to other members of the Ras superfamily (Table I ), suggesting that they play a distinct role in vesicular trafficking. The regions which confer homology to other members of the Ras superfamily are the amino acids underlined in Fig. 1 . These comprise the three highly conserved motifs involved in GTP binding and hydrolysis found in all GTP-binding proteins examined to date (Valencia et al., 1991; Wittinghofer and Pal, 1991) .
Mammalian Sarl Is Highly Enriched on Vesicular Carriers Found in the Transitional Region of the ER
To establish that the cDNAs isolated encoded functional Sarl proteins, Sarla and Sarlb cDNAs were cloned into the pQE9 vector to produce proteins containing histidine residues at their NH: termini (Hochuli et al., 1988) . These proteins were expressed in E. coli and purified by affinity chromatography on nickel-nitrolotriacetic acid (Ni-TCA)-agarose (Fig. 2, A and B) . Affinity-purified anti-Sarla antibody was prepared and its specificity examined by Western blotting. The polyclonal antibody recognized two prominent proteins in CHO lysates with molecular masses of 27 to 28 kD (Fig. 3) . 2), pQE-Sarlb (lanes 3 and 4), and pQE-Sarla-T39N (lanes 5 and 6) were grown to a density of A600 = 0.9 and further cultivated for 2 h at 37°C in the absence (lanes 1, 3, and 5) or in the presence (lanes 2, 4, and 6) of 2 mM isopropyl-thio-/~-D-galactoside. The mobilities of these two species correspond to the slightly differing mobilities of recombinant His-tagged Sarla and Sarlb (Fig. 3) , suggesting that these two species may be the endogenous proteins corresponding to the eDNA clones. The affinity-purified anti-Sarla antibody was used to determine the distribution of Sarl in mammalian cells. Using indirect immunofluorescence, Sarl was not routinely abundant in the extensive cisternae comprising the bulk of the ER membrane. Rather, Sarl was largely localized to the juxtanuclear Golgi region in NRK (Fig. 4 B) and CHO cells (Fig.  4 C) . In pancreatic insulin cells (Fig. 4 A) , the Sarla distribution had a more extended reticular pattern due to the highly amplified secretory compartments found in these cells. In general, the pattern of Sarl distribution is in part characteristic of the distribution of p53 and p58, markers for pre-Golgi intermediates which are abundant in the juxtanuclear Golgi region (Sehleifer et al., 1982; Schweizer et al., 1988 Schweizer et al., , 1990 Schweizer et al., , 1991 Saraste and Svensson, 1991) .
Using immunoelectron microscopy, Sarl immunogold particles were found in rat pancreatic insulin cells to be abun- dant on smooth transitional elements of the ER and on vesicular profiles in the proximal Golgi cisternae facing the transitional region (Fig. 5, A and B) . The transitional region contained clusters of immunolabeled 40-60-nm vesicles, together with clusters of unlabeled vesicles. Sarl was principally detected as a membrane-associated form (Table II) . Quantitation of the distribution of Sarl revealed that the carrier vesicles present in the transitional region were enriched approximately fourfold compared to the cis-Golgi cisternae and nearly 20-fold enriched compared to either the bulk of the ER or the trans-Golgi cisternae (Table II) . The density on the trans-Golgi face was similar to that found over the nucleus (Table H) , while the density over the bulk of the ER was approximately twofold greater than this level. Assuming the concentration of immunogold particles detected over the nucleus and the trans-Golgi compartments represents nonspecific background, then the enrichment of Sarl in the pre-Golgi vesicular carriers is exceptionally high (up to 40-50-fold). These results are, in part, consistent with indirect immunofluorescence studies in yeast where Sarlp was detected in a diffuse, perinuclear, and reticular localization which overlapped with Kar2p and Sec62p, both resident ER proteins (Nishikawa and Nakano, 1991) . Interestingly, Sarlp could also be detected in punctate structures in yeast which did not overlap with either ER or Golgi markers (Nishikawa and Nakano, 1991) . These may represent pre-Golgi intermediates.
Sarla(T39N) Inhibits Export of VSV-G from the ER In Vivo
To identify the potential role of Sarla in the regulation of ER to Golgi traffic in mammalian cells, mutations were generated with motifs involved in guanine nucleotide interactions. Extensive mutational and structural analysis of Ras and Rab proteins have defined the essential amino acid residues in these motifs which are involved in the binding and hydrolysis of GTP (reviewed in Barbacid, 1987; Bourne et al., 1991) . Two mutations were initially generated. These mutations are located in two of the four conserved guanine nucleotidebinding regions (Table III) . The first mutant, Sarla(N134I) contains a single point mutation (N134I) in the NKxD motif (residues 116-119 in p21 "-r~) which is essential for stabilization of the nucleotide-binding pocket (Pai et al., 1989 (Pai et al., , 1990 . The equivalent substitution in p21H-*~ (Nll6I) has a dominant negative phenotype and triggers oncogenic transformation. This mutant protein is defective in guanine nucleotide binding and has an exceptionally high exchange rate (Walter et al., 1986) . In yeast, the corresponding mutations in the yptl or sec4 alleles (involved in ER to Golgi and post-Golgi transport, respectively) result in dominant lethal phenotypes which correlate with severe secretory defects (Schmitt et al., 1986 (Schmitt et al., , 1988 Walworth et al., 1989) . In mammalian cells, an equivalent Rablb(N121I) mutant inhibits ER to Golgi transport resulting in the accumulation of VSV-G in pre-Golgi intermediates in vivo (Tisdale et al., 1992) and in vitro (Pind et al., 1994) .
The second mutant, Sarla(T39N) carries a substitution in the GxxxxGKS/T domain (residues 10-17 in p21H-~) which The amino acid sequences of sarl-related proteins, which make up GTP-binding domain, are compared t~ H-ras and other members of the ras superfamily. The numbering is that of H-ras. Mutations used in this study which alter GTP-binding for ras are indicated by the asterisk.
is involved in phosphate binding and Mg 2+ coordination (Pal et al., 1989 (Pal et al., , 1990 . It is analogous, in principle, to the p21"-~(S17N) mutant, which is restricted to the inactive (GDP-bound) conformation and inhibits cell proliferation (Feig and Cooper, 1988; Farnsworth et al., 1991) . The equivalent mutation in Rablb (Rablb [S22N] ), is a potent inhibitor of both ER to Golgi and intra-Golgi transport in vivo (Tisdale et al., 1992) and in vitro (Davidson and Balch, 1993; Nuoffer et al., 1994) . Competition experiments were performed to compare the relative affinities of the wild-type Sarla and the Sarla(T39N) mutant for GDP and GTP. The recombinant proteins were incubated with [3H]-GDP (1 /zM) in the presence of Mg 2+ (1 raM) and increasing concentrations of unlabeled GDP (Fig. 6 , open symbols) or GTP (Fig. 6, closed symbols) . As expected, in the case of both the wild-type protein or mutant proteins, supplementing the reaction with "01 #M GDP was sufficient to reduce pH]-GDP binding by ,050% (Fig. 6, open symbols) . However, an excess of GTP was necessary for half-maximal inhibition of [3H]-GDP binding for the wild-type and mutant proteins (Fig. closed symbols) , suggesting that both proteins have a higher affinity for GDP than GTP. Moreover, an "010-fold higher concentration of GTP was required for half-maximal inhibition of pH]-GDP binding to the Sarla(T39N) mutant that wild-type Sarla (Fig. 6 , closed symbols), indicating that the predominant consequence of the T39N substitution with respect to guanine nucleotide binding is to reduce the affinity of the protein for GTP without altering its affinity for GDP. To test if mutated forms of Sarl inhibit ER to the Golgi transport in intact mammalian ceils, a transient expression system was employed in which HeLa cells infected with vaccinia recombinant virus (vTF7-3) expressing "1"7 polymerase were cotransfected with a wild-type or mutant Sarla plasmid DNA and a plasmid encoding for VSV-G under control of the Figure 7 . Sarla(T39N) ("GDP") potently inhibits ER to Golgi transport in vivo. Transient expression of wild-type VSV-G in combination with Sarla wild-type (B) or mutant proteins (C and D) in vaccinia-infected Hela ceils was performed as described (Tisdale et al., 1992) . The mount of VSV-G remaining in the endo H-sensitive ER form (S), the amount processed to the cis/medial-Golgi intermediate endo H-resistant forms (RI) or the amount processed to the complex, sialic acid containing form (Rr) in terminal Golgi compartments was determined as described (Plutner et al., 1992; Tisdale et al., 1992; Davidson and Balch, 1993) . The control (A) contained only the VSV-G expression construct. T7 promoter (Tisdale et al., 1992) . Briefly, 4 h post-infection/transfection cells were pulsed with 35S-Met for 10 min. The pulse was followed by a chase for 90 min in the presence of unlabeled Met. The extent of transport of VSV-G from the ER to different Golgi compartments was quantitated by following the processing of VSV-G N-linked oligosaccharides acquired in the ER to various Golgi forms using SDS-PAGE (Tisdale et al., 1992) . In HeLa ceils, three distinct processed forms of VSV-G can be detected after increasing time of incubation during the chase period (Plutner et al., 1992; Tisdale et al., 1992; Davidson and Balch, 1993) . One form corresponds to the endo H-sensitive form found in the ER and pre-Golgi intermediates (S in Fig. 7) . A second form appears coincident with the transport of VSV-G to the early cis/ medial-Golgi compartments which generates an early endo H-resistant form lacking terminal Gal and sialic acid residues (R1 in Fig. 7) . Subsequently, VSV-G is processed in the terminal (trans) Golgi compartments to the complex forms containing Gal and terminal sialic acid (Rr in Fig. 7 ).
VSV-G was first cotransfected with the Sarla wild-type plasmid. As shown in Fig. 7 , the extent of VSV-G detected in the cis/medial R~ form (17%) or the trans/TGN Rr form (60%) was identical to the control lacking the Sarla wildtype plasmid (Fig. 7 b) . The level of expression of the Sarla wild-type and mutant proteins was generally two-to fourfold higher than the level of the endogenous Sarl pool based on Western blotting (data not shown). Thus, overexpression of wild-type Sarla neither inhibited nor stimulated transport. In contrast, overexpression of the Sarla(T39N) "GDP-bound" form strongly inhibited transport (Fig. 7 c) . In this case, less than 20% could be detected in the Rr terminally processed form, with over 70 % retained in pre-Golgi endo H-sensitive forms. A weak, but reproducible inhibition was also observed with Sarla(N134I) (Fig. 7 d) . In a typical experiment, 32% of the VSV-G remained in the endo H-sensitive S form as Compared to the control in which generally 20-22 % remained in the unprocessed form after a 90-min chase. The inability of this mutant to strongly inhibit transport may reflect its instability in vivo (see Discussion).
To determine the morphological site of inhibition by Sarla(T39N) in vivo, the distribution of VSV-G was examined using indirect immunofluorescence. In this case, HeLa cells were transfected with a plasmid expressing a thermoreversible form of VSV-G (tsO45) which fails to exit the ER when cells are incubated at the restrictive temperature (39.5°C) (Lafay, 1974) (Fig. 8 A) , but is efficiently transported to the Golgi when ceils are subsequently shifted to the permissive temperature (32°C) (Fig. 8 B, arrow) . When cells were cotransfected with tsO45 VSV-G and wild-type Sarla, transport to the Golgi was normal (Fig. 8 B) , consistent with the inability of the wild-type protein to prevent oligosaccharide processing during transient expression. In contrast, overexpression of Sarla(T39N) by two-to fourfold potently inhibited export from the ER (Fig. 8 C) . Quantitatively, >80-90% of the transfected cells failed to export VSV-G from the ER in the presence of Sarla(T39N). This result supports the interpretation that the role of mammalian Sarla, like that observed in yeast, is to regulate export from the ER.
Sarla Is Required for ER to Golgi Transport In Vitro
To examine the biochemical role of Sail in transport, we utilized an assay which efficiently reconstitutes ER to Golgi and intra-Golgi transport in semi-intact cells (Beckers et al., 1987; Baker et al., 1988; Schwaninger et al., 1991; Plutner et al., 1992; Davidson and Balch, 1993) . The assay was supplemented with UDP-GlcNAc to promote processing of VSV-G to the R~ endo H-resistant form (Davidson and Balch, 1993) . Addition of affinity-purified antibody was Figure 8 . Transient expression of Sarla(T39N) in vivo inhibits the export of VSV-G from the ER. Vaccinia-infected HeLa cells were transfected with a plasmid expressing the temperature-sensitive (tsO45) form of VSV-G for 4 h at 39.5°C. 4 h after transfection, cells were either retained at the restrictive temperature (39.5°C) (A) or shifted to the permissive temperature (32°C) and incubated for 2 h in the presence of wild-type Sarla (B) or Sarla(T39N) (C) as described previously (Tisdale et al., 1992) . Cells were fixed, permeabilized, and the distribution of tsO45 VSV-G determined as described previously (Plutner et al., 1992) . In (B, arrow) , VSV-G exactly overlaps with Lens culinaris lectin which binds principally to terminal N-acetylglucosamine, a marker for cis/medial compartments of the Golgi. found to inhibit ER to Golgi transport by >90% (Fig. 8, open  circles) . Inhibition was specific since incubation of the antibody in the presence of recombinant Sarla wild-type protein at molar excess neutralized inhibition (Fig. 9, closed circles) . Since the antibody inhibition may result from aggregation of Sarla in the membrane, F,b fragments were prepared and also found to potently inhibit transport (data not shown). In contrast, when the effects of the antibody were tested on an assay which reconstitutes the transport of VSV-G between isolated Golgi stacks, no significant inhibition was observed (Fig. 9, inset) . These results provide evidence that Sarl may be a GTPase required for export of protein from the ER, but not for transport through subsequent compartments of the Golgi complex.
Given the striking effects of expression of Sarla(T39N) on ER to Golgi transport in vivo (Figs. 7 and 8) , the effect of (T39N). (B, inset) Semi-intact cells were incubated in the presence of either 5 ttg Sarla wild-type or Sarla(T39N) for 75 min. The amount of VSV-G processed to either the RI or Rr forms in the presence of UDP-GIcNAc, UDP-Gal and CMP-SA was determined as described (Davidson and Balch, 1993) . (C) Isolated Golgi stacks were incubated in the presence of increasing concentration of Sarla wild-type or Sarla(T39N) as described in Materials and Methods. The extent of [3H]-GIcNAc incorporated is expressed as the % of the control level of transport lacking additional Sarla protein.
recombinant Sarla wild-type and the T39N mutant on VSV-G transport in vitro was examined. As shown in Fig. 10 A, addition of increasing concentrations Sarla(T39N) inhibited transport in vitro by nearly 95 %. Transport hras inhibited by 50 % in the presence of ~ 2.5 ~g Sarla(T39N) with maximal inhibition above 5 tzg. No inhibition was detected in the presence of an equivalent concentration of the wildtype protein (Fig. 10 A) . The level of inhibition by the mutant was found to vary between different preparations of recombinant protein. The most active preparation inhibited transport with an IC5o of 0.5 Izg with maximal inhibition in the presence of 1.5 #g.
Transport of VSV-G from the ER to the cis-Golgi compartment generally has a 15-20-min lag period during which time 40-80-nm carrier vesicles bud and target to the cis face of the Golgi stack (Plutner et al., 1992; Balch et al., 1994) . To determine whether Sarla was required for an early step reflecting vesicle budding or a later step involved in targeting or fusion, the T39N mutant protein was added at increasing time after initiation of transport. As shown in Fig. 10 B, transport became rapidly (within 5-10 min) insensitive to the addition of Sarla(T39N) to the assay. For example, after only 10 rain of incubation in vitro, a time-point in which Golgi processed forms of VSV-G cannot be detected, >60% of the total VSV-G transported in the control lacking Sarla(T39N) was processed to the endo H-resistant R, form in the presence of the mutant (Fig. 10 B) . Therefore, Sarla is clearly recruited at a very early step in transport. Is Sarl required only for export of protein from the ER, or, is it required also for vesicle formation from Golgi compartments? To address this question directly semi-intact cells were incubated in vitro in the presence of the sugar nucleotide precursors UDP-GlcNAc, UDP-Gal, and CMP-SA to promote the processing of VSV-G to the terminally glycosylated (RT) form during transport to the trans-Golgi compartment (Davidson and Balch, 1993) . As shown in Fig.  10 B (inset) , in the presence of wild-type Sarla, VSV-G was efficiently processed to the R~ (22%) and R7 (50%) forms after a 90-rain incubation, similar to control values obtained in the absence of exogenous Sarla. In contrast, in the presence of the T39N mutant the small proportion of VSV-G which was exported from the ER (18 % of total) was quantitatively chased to the mature, RT form with less than 5% found in the Rt form, suggesting that the mutant was incapable of blocking intra-Golgi transport.
To pursue the above important observation, we examined the effect of the addition of the Sarl(T39N) mutant after increasing times of incubation. As a control, GTP,ySt (a nonhydrolyzable analog of GTP which inhibits both ER to Golgi and intra-Golgi transport in semi-intact cells [Beckers and Balch, 1989; Schwaninger et al., 1992; Davidson and Balch, 1993] ) was added in a parallel set of incubations. In these experiments, addition of the reagent was followed by further incubation of cells for a total time of 120 rain to allow any VSV-G which had matured past a particular T39N-or GTP,yS-sensitive step(s) to be processed in the subsequent Golgi compartment(s) (Fig. 11) . As illustrated in Fig. 11 A and quantitated in Fig. 11 , B-D, whereas GTP-yS led to the accumulation of VSV-G in the Rt form when added to early time points (see Fig. 11 C) , addition of Sarla(T39N) consistently led to maturation of VSV-G to the RT form with little accumulation in the R~ form (see Fig. 11, C and D) . In each case, the inhibitory effect of the mutant (or GTP~S) preceded processing by •5-10 min, consistent with the notion that both reagents inhibit an early step in vesicle function. Thus, it is evident that while the general reagent GTP'yS inhibits vesicle formation between multiple compartments, Sat1 is required only for export from the ER.
The effects of Sarla were also examined using an assay which reconstitutes the transport of VSV-G between isolated Golgi stacks (Balch et al., 1984) . When Sarla(T39N) was added at a concentration sufficient to inhibit ER to Golgi transport by >80% (5 ~tg) (Fig. 10 A) only partial inhibition of transport was observed. In this case, inhibition was less than 25 % of a control incubation containing an equivalent concentration of wild-type Sarla (Fig. 10 C) . The latter protein also partially inhibited (by *25%) transport. The weak inhibition of transport between isolated Golgi stacks by either the wild-type or Sarla(T39N) mutants may reflect nonspecific effects of the recombinant protein on the assay. Neither wild-type nor mutant Sarla were found to have any effect Figure 12 . Sarla T39N inhibits the export of VSV-G from the ER in vitro. Cell permeabilization, incubation conditions, and morphological analysis of transport using indirect immunofluorescence were performed as described (Plutner et al., 1992) . (A and B) Distribution of VSV-G (A) and Man 1I (B, arrows) prior to incubation in vitro. Man II is a marker protein for the cis/medial-Golgi compartments in NRK cells (Plutner et al., 1992; Velasco et al., 1993) . (C and D) Transport of VSV-G in cells incubated for 45 min at 32°C in vitro to pre-Golgi intermediates (C, open arrows) and Golgi compartments (C, VSIZ-G, arrows; D, Manll, arrows) in the presence of 5 #g Sarla wild-type protein. The structures denoted by the open arrows in C overlap with the distribution of the pre-Golgi marker protein p58 (Saraste and Svensson, 1991) (not shown). (E and F) Distribution of VSV-G (E) and Golgi (F,, Manll, arrows) in permeabilized ceils incubated for 45 rain at 32°C in the presence of 5 #g of Sarla(T39N). Small arrows in (E) denote transport of VSV-G to punctate, pre-Golgi intermediates which overlap with the distribution of p58 (not shown).
on the steady state distribution of B-COP on Golgi compartments (data not shown).
Sarla(T39N) Specifically Inhibits Budding from the ER In Vitro
To identify the step in transport between the ER and the Golgi which requires Sarl, digitonin-permeabilized cells (Plumer et al., 1992) were incubated for 45 min in the presence of the mutant protein and the distribution of tsO45 VSV-G was examined using indirect immunofluorescence. As shown in Fig. 12 , prior to incubation in vitro, VSV-G is restricted to the ER (Fig. 12 A) . As expected, incubation of cells in the presence of the Sarla wild-type protein leads to the efficient transport of VSV-G from the ER to pre-Golgi intermediates (Fig. 12 C, open arrows) and compartments of the Golgi stack containing the Golgi marker enzyme a-l,2 mannosidase II (compare Fig. 12, C and D, arrows) . In contrast, incubation in the presence of the T39N mutant largely inhibited exit from the ER (Fig. 12 E) . Most of the VSV-G was retained in a diffuse ER staining pattern, although some migration of VSV-G to punctate pre-Golgi could be detected (Fig. 12 E, small arrows) , presumably reflecting the small amount of VSV-G able to escape the block at this concentration of T39N. Addition of an inhibitory concentration of the afffinity-purified Sarl-specific antibody also completely prevented export of VSV-G from the ER in vitro (not shown). These data are consistent with the results observed in vivo (Fig. 7) , and suggest that the Sarl GDP-bound mutant rapidly and efficiently competes with the endogenous wild-type pool for an effector molecule critical for the generation of transport vesicles from the ER.
Discussion
Sarl Is Enriched on ER to Golgi Carrier Vesicles in Mammalian Cells
The localization of Sarl to the transitional region of the ER provides one of several lines of evidence that it functions in ER to Golgi transport. Sarla was enriched 20-40-fold on putative ER to Golgi carrier vesicles and nearly 10-fold in the transitional region relative to its distribution in the bulk of the ER membrane. Transitional elements are believed to be specialized sites of export of newly synthesized protein from the labyrinth of rough Ell (RER), an organelle which is exceptionally abundant in insulin-secreting pancreatic cells. In contrast to Art (Stearns et al., 1990) or Rabl/Ypflp (Segev et al., 1988; Plutner et al., 1991; Pind et al., 1994) , which are abundant on pre-Golgi carrier vesicles and multiple compartments of the Golgi stack, Sarl was confined to the cisternal elements of the proximal face of the Golgi. In yeast, Sarlp has been detected using indirect immunofluorescence on perinuclear ER elements which contain Kar2p and Sec62p, and small punctate structures which are likely to be pre-Golgi intermediates, but not in Golgi compartments containing the KEX2 gene product, a trans-Golgi marker (Nishikawa and Nakano, 1991) . Sarlp has also been detected in exaggerated ER structures which accumulate at the restrictive temperature in the presence of the temperaturesensitive secl2 and secl8 alleles, but was not detected in Golgi-like compartments which accumulate at the restrictive temperature in the presence of either the secl or sec7 mutant alleles (Nishikawa and Nakano, 1991) . Consistent with the distribution of mammalian Sarlp, a protein which crossreacts with an antibody specific for the yeast Sarlp-specific GAP (Sec23p) has also been localized to the transitional region of the ER in insulin-secreting cells .
Two additional lines of evidence support a role for Sarl in vesicle budding from the ER. First, a Sarl-specific antibody inhibited export, possibly by preventing the assembly of a Sarl-regulated coat complex. Second, the T39N mutant was a potent inhibitor of transport of VSV-G between the ER and the cis-Golgi compartment. While we reported inhibition of transport based on the inability of VSV-G to be processed to the endo H-resistant R1 form, we have observed identical levels of inhibition in the processing of VSV-G to the endo D-sensitive, 5 mannose (Mans) containing form in a CHO cell line (clone 15B) defective in modification of VSV-G NH2-1inked oligosaccharides beyond the Man5 structure (Rowe, T. and W. E. Balch, unpublished observations). This processing intermediate immediately precedes the appearance of the R1 form and is a hallmark for delivery of VSV-G protein to the cis-Golgi compartment (Beckers et al., 1987; Plutner et al., 1992; Davidson and Balch, 1993) .
How does the Sarla(T39N) mutant inhibit export? This mutation is equivalent to the S17N substitution in p21 e .... which disrupts the contribution of the hydroxyl group of Set-17 to the Mg 2+ ion involved in guanine nucleotide binding (Feig and Cooper, 1988; Farnsworth et al., 1991) . This abolishes the high affinity of p21 ~-r~ for GTP producing a GDPbound form. Improper complexing of Mg 2+ also restricts p21R-~ to a conformationally inactive state. The S17N mutant is believed to interfere with wild-type Ras function in vivo by serving as a competitive inhibitor for the nucleotide exchange factor (GEF), thereby preventing GDP/GTP exchange on the endogenous wild-type pool and leading to inhibition of cell growth (Farnsworth et al., 1991) . The capacity of the Sarla(T39N) mutant to efficiently inhibit export from the ER suggests that it is rapidly equilibrated with the endogenous, functional Sarl pool. Given the altered guanine nucleotide binding properties of the Sarla(T39N) mutant, a reasonable interpretation at this time is that the T39N mutant may compete with the wild-type protein for a Sarla-speeific GEE interfering with the recruitment of Sarl to the ER membrane. This interpretation is consistent with the effects of a temperature-sensitive allele of the Sarlp-specific exchange factor (Secl2p-GEF) which, in yeast leads to the proliferation of ER elements in cells incubated at the restrictive temperature (Novick et al., 1980; Nakano et al., 1988) . The reduced ability of the Sarlp-GEF in the presence of the T39N mutant to support vesicle budding is consistent with the proposed role of other GEF's involved in the recruitment and activation of Art (Donaldson et al., 1992a,b; Helms and Rothman, 1992; Daseher and Balch, 1994) , Rabl (Nuoffer et al., 1994) , and SEC4 (Moya et al., 1993) . In general, molecules promoting nucleotide exchange may play a crucial first step in the recruitment and subsequent activation of small GTP-bindlng proteins involved in vesicular transport between compartments of the exocytic and endocytic pathways.
The N134I substitution was considerably less potent than the T39N mutant in inhibiting ER to Golgi transport. We found this surprising given the fact that equivalent mutations in Rabla (N124I), Rablb(N121D, and Rab2 (N1191I) are potent trans dominant inhibitors of ER to Golgi transport in vivo and in vitro (Tisdale et al., 1992; Pind et al., 1994) . Rabl mutants allow vesicles to bud from the Ell, but prevent their fusion to the cis-Golgi compartment (Tisdale et al., 1992; Pind et al., 1994) . In yeast, the equivalent yptl or see4 mutant alleles are dominant lethal with marked secretory defects (Schmitt et al., 1986 (Schmitt et al., , 1988 Walworth et al., 1989) . In the case of p21H-~', the Nll6I substitution destabilizes the nucleotide-bindlng pocket (Der et al., 1986; Feig and Cooper, 1988; John et al., 1993) , resulting in a high exchange rate. This altered conformation restricts p21H-r.s to the activated state, triggering oncogenic transformation (Walter et al., 1986) . One possible explanation for the inability of Sarla(N134I) to inhibit transport is that the folding or stability of the protein is compromised. Consistent with this interpretation, we found that expression of the Sarla(N134I) mutant in E. coli leads to extensive aggregation. Unlike similar mutations in Rabl (Nuoffer et al., 1994; Pind et al., 1994) , we have been unable to purify a soluble form of the N134I mutant to test its function in vitro. Further analysis of this mutant and a mutant restricted to the GTP-form are currently under investigation.
Sarl, a GTPase Specific for Export from the ER
The striking enrichment of Sarl on transitional carrier vesicles, and the ability of both Sarl-specific antibodies and the T39N mutant to inhibit ER to Golgi, but not intra-Golgi transport in semi-intact cells, supports the conclusion that Sarl regulates vesicle budding at only one step of the secretory pathway-export from the ER. While the biochemical evidence for this interpretation is compelling, it is inconsis-tent with data from a genetic analysis in yeast where SEC23 (Sarlp-GAP) function was required for at least two sequential steps: transport from the ER to the cis-Golgi compartment, and between early, but not late Golgi compartments (Graham and Emr, 1991) . At this time there are three possible explanations for this apparent contradiction. One possibility, albeit one which we consider unlikely, is that the compartmental organization of the early secretory pathway in yeast is different from that found in mammalian cells. Alternatively, an interpretation of the genetic analysis which cannot be ruled out is that Sarlp/Sec23p are essential for delivery of factor(s) which is subsequently required for transport between early, but not late Golgi compartments (Graham and Emr, 1991) . Finally, it remains to be established whether a larger Sar gene family exists, similar to that observed for Rab and which may contain many more divergent species specialized for individual stages of the exocytic (or endocytic) pathway. In this case, Sec23p may serve as a common GAP for several of these related GTPases. In any case, the presence of Sarlp on the cis-face of the Golgi stack is consistent with the possibility that this distribution represents its site of recycling for reuse in multiple rounds of transport.
The requirement for a unique GTPase-regulating export from the ER is intriguing given recent evidence that export of protein from the ER may involve both the sorting and concentration of cargo from resident ER proteins during vesicle budding ( 
